Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR | Market Cap | 1.02T -5.0% |
| Revenue (ttm) | 329.84B -3.6% |
| Net Income | 27.99B -52.3% |
| EPS | 33.58 -52.3% |
| Shares Out | 832.98M |
| PE Ratio | 36.46 |
| Forward PE | 23.84 |
| Dividend | 8.00 (0.65%) |
| Ex-Dividend Date | Jul 10, 2026 |
| Volume | 306,106 |
| Open | 1,234.70 |
| Previous Close | 1,239.00 |
| Day's Range | 1,215.35 - 1,251.00 |
| 52-Week Range | 1,080.05 - 1,414.40 |
| Beta | 0.25 |
| Analysts | Hold |
| Price Target | 1,283.65 (+4.83%) |
| Earnings Date | Oct 23, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as ... [Read more]
Financial Performance
In fiscal year 2026, Dr. Reddy's Laboratories's revenue was 335.93 billion, an increase of 3.19% compared to the previous year's 325.54 billion. Earnings were 42.85 billion, a decrease of -24.22%.
Financial StatementsAnalyst Summary
According to 37 analysts, the average rating for 500124 stock is "Hold." The 12-month stock price target is ₹1,284, which is an increase of 4.83% from the latest price.
News
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidom...
Dr. Reddy's Laboratories Transcript: Q2 26/27
Revenue declined 1.5% YoY as lower lenalidomide sales offset double-digit growth in the underlying business. Gross margin was 52.1%; management expects semaglutide validation and relaunch in November, with EBITDA margins above 20% targeted.
Dr. Reddy's Laboratories Quarterly report: Q2 2027
Dr. Reddy's Laboratories has published its Q2 2027 quarterly earnings report on October 23, 2026.
Dr. Reddy's Laboratories Slides: Q2 2027
Dr. Reddy's Laboratories has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 23, 2026.
Dr Reddy’s Labs gets CDSCO nod for Zytorvi use in esophageal squamous cell carcinoma
Dr Reddy’s gets CDSCO approval for Zytorvi (toripalimab) with chemo as first-line treatment for advanced ESCC in adults, backed by Phase 3 data.
RDY Crosses Above Key Moving Average Level
In trading on Tuesday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $13.21, changing hands as high as $13.35 per share. Dr. Reddy's Laboratories ...
Dr. Reddy’s upgraded to Outperform from Neutral at BNP Paribas
BNP Paribas analyst Tausif Shaikh upgraded Dr. Reddy’s (RDY) to Outperform from Neutral with a $14.80 price target
Dr Reddy's, Nestle, Amazon, Flipkart Get Notice Over Misleading Health Claims
The regulator said such claims were presented on product packaging in a manner that could potentially mislead consumers about the health benefits associated with the products.
Dr. Reddy’s double-upgraded to Buy from Sell at Citi
Citi analyst Vivek Agrawal upgraded Dr. Reddy’s (RDY) to Buy from Sell with a price target of INR 1,450, up from INR 1,040. While North America revenues are expected to…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such invest...
Top stocks to buy today: Stock market recommendations for September 22, 2026 - check list
Stock market recommendations: LIC Housing Finance, Supreme Industries, Hitachi Energy India, and Dr Reddy's Laboratories - these are the top stocks to buy on September 22, 2026 as recommended by Somil...
Dengue vaccine to hit market by first half of 2027
India News: NEW DELHI: India's first dengue vaccine is expected to be available in the private market in the first half of 2027. Takeda Pharma and Dr Reddy's Labo.
Dr Reddy’s inks pact with Takeda for rollout of dengue vaccine in India
Dr Reddy’s signs exclusive pact with Takeda to distribute dengue vaccine Qdenga in India’s private market; CDSCO approved July 2026, launch expected H1 2027.
Dr Reddy’s inks pact with Takeda for rollout of Qdenga vaccine
Dr Reddy’s signs exclusive pact with Takeda to distribute dengue vaccine Qdenga in India’s private market; CDSCO approved July 2026; launch expected H1 2027.
Dr Reddy’s inks pact with Takeda for distribution of dengue vax Qdenga in India’s private market
Dr Reddy’s signs exclusive deal with Takeda to promote and distribute dengue vaccine Qdenga in India’s private market; CDSCO-approved for ages 4-60, launch expected H1 2027.
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
Dr Reddy’s inks licensing deal with Gilead for once-yearly HIV lenacapavir
Dr Reddy’s signs royalty-free, non-exclusive voluntary licence with Gilead for investigational once-yearly lenacapavir PrEP in 120 high-incidence countries.
Dr Reddy's Laboratories Ltd (RDY) Shares Fall 3.0% -- What GF Score of 85 Tells Investors
Dr Reddy's Laboratories Ltd (RDY) Shares Fall 3.0% -- What GF Score of 85 Tells Investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such invest...
Dr Reddy’s forays into Indian biosimilar immuno-oncology market
Dr Reddy’s launches Nivorz, a biosimilar of Opdivo (nivolumab), in India; DCGI approves it for 12 cancer indications after multi-country trials.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such invest...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such invest...